-

Agenus to Provide Second Quarter 2023 Financial Report and Corporate Update

Company Announces Participation in BTIG Virtual Biotechnology Conference

LEXINGTON, Mass.--(BUSINESS WIRE)--Immuno-oncology leader, Agenus (Nasdaq: AGEN), today announced the Company will release its second quarter 2023 financial results via press release before the market opens on Tuesday, August 8, 2023.

In addition, Dr. Garo Armen, Chairman and CEO of Agenus, will participate in the following upcoming investor conferences:

  • BTIG Virtual Biotechnology Conference 2023 – Fireside chat presentation will be held virtually on Monday, August 7th, 2023 at 3:00 PM ET.

A replay of the fireside chat from the BTIG conference can be accessed on the company’s website at https://investor.agenusbio.com/events-and-presentations following the event.

About Agenus

Agenus is a leading immuno-oncology company targeting cancer and infectious diseases with a comprehensive pipeline of immunological agents. The Company’s mission is to expand patient populations benefiting from cancer immunotherapy through combination approaches, using a broad repertoire of antibody therapeutics, adoptive cell therapies (through MiNK Therapeutics), and adjuvants (through SaponiQx). Agenus is headquartered in Lexington, MA. For more information, visit www.agenusbio.com or follow us on LinkedIn and Twitter @agenus_bio.

Contacts

Investor Contact
Zack Armen
917-362-1370
investors@agenusbio.com

Media Contact
781-674-4784
communications@agenusbio.com

Industry:

Agenus

NASDAQ:AGEN
Release Versions
English

Contacts

Investor Contact
Zack Armen
917-362-1370
investors@agenusbio.com

Media Contact
781-674-4784
communications@agenusbio.com

More News From Agenus

Agenus to Present New Data at AACR-IO Exploring Systemic and Tumor Inflammation Biomarkers with BOT/BAL in Immunologically Cold Tumors

LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today announced that new translational and clinical biomarker analyses from its botensilimab (BOT) immunotherapy program have been accepted for poster presentation at the American Association for Cancer Research- Immuno-Oncology (AACR-IO) Conference, taking place in Los Angeles, CA on February 18–21, 2026. The abstract, titled “Systemic and tumor-microenvironment inflammation shape outcomes in patients w...

Agenus Expands Medical Affairs Infrastructure to Support Increasing Physician Requests for Authorized Access to Botensilimab Plus Balstilimab

LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced the expansion of its global Medical Affairs infrastructure and early-access support capabilities in response to increasing physician-initiated interest regarding authorized access to the investigational immunotherapy combination botensilimab plus balstilimab (BOT+BAL). The expansion reflects increasing interest from treating oncologists worldwide seeking access to BOT+BAL for p...

Agenus to Host First 2026 Stakeholder Webcast

LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in immuno-oncology, today announced it will host its first Stakeholder Webcast of 2026, Access to Acceleration: Agenus’ Global Momentum Entering 2026 on Wednesday, January 28, 2026, at 4:00 p.m. ET. The webcast will highlight how expanding global access pathways, strategic partnerships, and operational readiness are driving momentum for Agenus’ botensilimab and balstilimab (BOT+BAL) program entering 2026. The ses...
Back to Newsroom